{'52WeekChange': -0.5966562,
 'SandP52WeekChange': 0.0644362,
 'address1': '320 Wakara Way',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 11.59,
 'askSize': 900,
 'averageDailyVolume10Day': 713275,
 'averageVolume': 1239741,
 'averageVolume10days': 713275,
 'beta': 1.284593,
 'beta3Year': None,
 'bid': 11.57,
 'bidSize': 1300,
 'bookValue': 12.983,
 'category': None,
 'circulatingSupply': None,
 'city': 'Salt Lake City',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 12.23,
 'dayLow': 11.51,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': 68.241,
 'enterpriseToRevenue': 1.283,
 'enterpriseValue': 975843456,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '801-584-3640',
 'fiftyDayAverage': 12.304857,
 'fiftyTwoWeekHigh': 48.4,
 'fiftyTwoWeekLow': 9.24,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 65483631,
 'forwardEps': 0.48,
 'forwardPE': 24.125,
 'fromCurrency': None,
 'fullTimeEmployees': 2600,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.01759,
 'heldPercentInstitutions': 1.07181,
 'industry': 'Diagnostics & Research',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1561852800,
 'lastMarket': None,
 'lastSplitDate': 1238025600,
 'lastSplitFactor': '2:1',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/myriad.com',
 'longBusinessSummary': 'Myriad Genetics, Inc., a molecular diagnostic '
                        'company, develops and markets predictive, '
                        'personalized, and prognostic medicine tests '
                        'worldwide. The company offers myRisk Hereditary '
                        'Cancer, a DNA sequencing test for hereditary cancers; '
                        'BRACAnalysis, a DNA sequencing test to assess the '
                        'risk of developing breast and ovarian cancer; and '
                        'riskScore, a personalized medicine tool. It also '
                        'provides BRACAnalysis CDx, a DNA sequencing test for '
                        'use in identifying ovarian and HER2 negative '
                        'metastatic breast cancer patients with deleterious or '
                        'suspected deleterious germline; GeneSight, a DNA '
                        'genotyping test to aid psychotropic drug selection '
                        'for depressed patients; and Vectra, a protein '
                        'quantification test for assessing the disease '
                        'activity of rheumatoid arthritis. In addition, the '
                        'company offers Foresight, a prenatal test for future '
                        'parents to assess their risk of passing on a '
                        'recessive genetic condition to their offspring; '
                        'Prequel, a non-invasive prenatal screening test to '
                        'screen for severe chromosomal disorders in a fetus; '
                        'and Prolaris, a RNA expression test for assessing the '
                        'aggressiveness of prostate cancer. Further, it '
                        'provides EndoPredict, a RNA expression test for '
                        'assessing the aggressiveness of breast cancer; myPath '
                        'Melanoma, a RNA expression test for diagnosing '
                        'melanoma; and myChoice HRD, a companion diagnostic to '
                        'measure three modes of homologous recombination '
                        'deficiency comprising loss of heterozygosity, '
                        'telomeric allelic imbalance, and large-scale state '
                        'transitions in cancer cells. Additionally, the '
                        'company offers biomarker discovery, and '
                        'pharmaceutical and clinical services to the '
                        'pharmaceutical, biotechnology, and medical research '
                        'industries; and operates an internal medicine '
                        'emergency hospital primarily for internal medicine '
                        'and hemodialysis. The company has collaboration with '
                        'AstraZeneca for the development of an indication for '
                        'BRACAnalysis CDx. Myriad Genetics, Inc. was founded '
                        'in 1991 and is headquartered in Salt Lake City, Utah.',
 'longName': 'Myriad Genetics, Inc.',
 'market': 'us_market',
 'marketCap': 863343488,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_31822',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -148300000,
 'nextFiscalYearEnd': 1625011200,
 'open': 12.23,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -10.86,
 'phone': '801-584-3600',
 'previousClose': 12.32,
 'priceHint': 2,
 'priceToBook': 0.8919356,
 'priceToSalesTrailing12Months': 1.1347837,
 'profitMargins': -0.19493,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 12.23,
 'regularMarketDayLow': 11.51,
 'regularMarketOpen': 12.23,
 'regularMarketPreviousClose': 12.32,
 'regularMarketPrice': 12.23,
 'regularMarketVolume': 703805,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 74554704,
 'sharesPercentSharesOut': 0.14649999,
 'sharesShort': 10925515,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 7407362,
 'shortName': 'Myriad Genetics, Inc.',
 'shortPercentOfFloat': 0.31,
 'shortRatio': 6.33,
 'startDate': None,
 'state': 'UT',
 'strikePrice': None,
 'symbol': 'MYGN',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.007,
 'twoHundredDayAverage': 16.704102,
 'volume': 703805,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://myriad.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '84108'}